Henry Schein (HSIC) Getting Somewhat Positive Media Coverage, Report Shows
Headlines about Henry Schein (NASDAQ:HSIC) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Henry Schein earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.9058234012245 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media headlines that may have effected Accern’s scoring:
- Henry Schein, Inc. (HSIC) Expected to Post Earnings of $0.97 Per Share (americanbankingnews.com)
- Henry Schein (HSIC) Buys ABASE, Expands in Animal Health (finance.yahoo.com)
- Kimberly-Clark Corporation (KMB) Swings on Assorted News – Henry Schein, Inc. (HSIC) – Investing News Update (investingbizz.com)
- Keep Your Active Eyes on Henry Schein, Inc. (HSIC) – Wall Street Morning (wallstreetmorning.com)
- Henry Schein, Inc. (HSIC) to Post Q3 2018 Earnings of $1.14 Per Share, William Blair Forecasts (americanbankingnews.com)
Henry Schein (NASDAQ:HSIC) traded up $1.20 during trading on Tuesday, reaching $76.04. 2,080,000 shares of the company’s stock traded hands, compared to its average volume of 1,620,000. The company has a current ratio of 1.55, a quick ratio of 0.86 and a debt-to-equity ratio of 0.30. Henry Schein has a 52-week low of $65.28 and a 52-week high of $93.50. The company has a market cap of $11,930.00, a price-to-earnings ratio of 21.91, a price-to-earnings-growth ratio of 1.91 and a beta of 0.99.
Henry Schein declared that its board has initiated a stock repurchase program on Monday, September 18th that permits the company to buyback $400.00 million in shares. This buyback authorization permits the company to reacquire up to 6.3% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board believes its shares are undervalued.
A number of brokerages recently issued reports on HSIC. Jefferies Group reiterated a “hold” rating and issued a $88.50 price objective on shares of Henry Schein in a report on Thursday, September 28th. Evercore ISI began coverage on shares of Henry Schein in a report on Thursday, January 4th. They issued an “outperform” rating and a $81.00 price objective for the company. Leerink Swann reiterated a “market perform” rating and issued a $77.00 price objective (down previously from $87.50) on shares of Henry Schein in a report on Tuesday, November 7th. Stephens began coverage on shares of Henry Schein in a report on Tuesday, November 28th. They issued an “equal weight” rating and a $76.00 price objective for the company. Finally, Royal Bank of Canada began coverage on shares of Henry Schein in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $91.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company. Henry Schein has a consensus rating of “Hold” and a consensus price target of $84.23.
In other Henry Schein news, Director Barry J. Alperin sold 5,796 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $70.76, for a total transaction of $410,124.96. Following the completion of the transaction, the director now owns 48,172 shares in the company, valued at approximately $3,408,650.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.19% of the stock is currently owned by company insiders.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.